Last reviewed · How we verify
Deferred aflibercept
Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), binding and neutralizing these pro-angiogenic factors.
Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), binding and neutralizing these pro-angiogenic factors. Used for Diabetic macular edema (DME), Retinal vein occlusion (RVO), Age-related macular degeneration (AMD).
At a glance
| Generic name | Deferred aflibercept |
|---|---|
| Also known as | intravitreal anti-vascular endothelial growth factor, Eylea, intravitreal anti-VEGF |
| Sponsor | Jaeb Center for Health Research |
| Drug class | VEGF inhibitor / Antiangiogenic agent |
| Target | VEGF (vascular endothelial growth factor), PlGF (placental growth factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Oncology |
| Phase | Phase 3 |
Mechanism of action
Aflibercept functions as a VEGF trap by combining the extracellular domains of VEGF receptors 1 and 2 fused to the Fc portion of human IgG1. This construct binds circulating VEGF and PlGF with high affinity, preventing their interaction with endothelial cell receptors and thereby inhibiting pathological angiogenesis and vascular permeability. The 'deferred' designation likely refers to a delayed-treatment or treatment-deferral study design rather than a mechanistic modification.
Approved indications
- Diabetic macular edema (DME)
- Retinal vein occlusion (RVO)
- Age-related macular degeneration (AMD)
Common side effects
- Conjunctival hemorrhage
- Eye pain / discomfort
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
Key clinical trials
- High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes (PHASE4)
- A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME) (PHASE4)
- DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME (PHASE3)
- Anti-VEGF Treatment for Prevention of PDR/DME (PHASE3)
- IVI Aflibercept Before and After Phaco in DME. (NA)
- Anti-VEGF vs. Prompt Vitrectomy for VH From PDR (PHASE2, PHASE3)
- Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept (NA)
- Treatment for CI-DME in Eyes With Very Good VA Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Deferred aflibercept CI brief — competitive landscape report
- Deferred aflibercept updates RSS · CI watch RSS
- Jaeb Center for Health Research portfolio CI